Related Experiment Video

Updated: Jun 9, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors

L Romayne Kurukulasuriya1, James R Sowers

  • 1Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, D109 Diabetes Center, UMC, One Hospital Drive, Columbia, MO 65212, USA. kurukulasuriyar@health.missouri.edu

Cardiovascular Diabetology
|September 1, 2010
PubMed
Abstract

Insights

Antidiabetes agents effectively manage glucose, but their impact on cardiovascular risk factors like weight, lipids, and blood pressure varies significantly. Optimal treatment requires a comprehensive approach addressing both glycemic control and cardiovascular health in type 2 diabetes.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Type 2 diabetes necessitates aggressive management of cardiovascular risk factors.
  • Glycemic control is paramount, but agent-specific effects on weight, lipids, and blood pressure are critical considerations.

Purpose of the Study:

  • To review and summarize the effects of various antidiabetes agents on glucose control.
  • To evaluate the impact of these agents on key cardiovascular risk factors.
  • To inform the selection of optimal therapeutic regimens for type 2 diabetes management.

Main Methods:

  • Systematic review of studies on antidiabetes agents.
  • Analysis of effects on glycemic control, body weight, lipid levels, and blood pressure.
  • Synthesis of data to guide treatment selection.

Main Results:

  • All antidiabetes pharmacotherapies reduce glucose levels.
  • Weight effects vary: weight gain (thiazolidinediones, sulfonylureas, insulin), weight neutral (DPP-4 inhibitors), weight loss (metformin, GLP-1 RAs, amylinomimetics).
  • Metformin, thiazolidinediones, insulin, and GLP-1 RAs show benefits for lipid and blood pressure parameters.

Conclusions:

  • Effective management of type 2 diabetes requires a multidisciplinary strategy.
  • Treatment must address both glycemic targets and underlying cardiovascular risk factors.
  • Individualized therapeutic regimens are essential for optimal patient outcomes.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...